

# Supporting Information

for

## Chemoenzymatic synthesis of mono- and di-fluorinated Thomsen-Friedenreich (T) antigens and their sialylated derivatives

Jun Yan,<sup>a</sup> Xi Chen,<sup>b</sup> Fengshan Wang,<sup>\*a,c</sup> and Hongzhi Cao<sup>\*a,d</sup>

<sup>a</sup> National Glycoengineering Research Center, School of Pharmaceutical Science, Shandong University, Jinan 250012, China.

<sup>b</sup> Department of Chemistry, University of California, One Shields Avenue, Davis, California 95616, USA.

<sup>c</sup> Key Laboratory of Chemical Biology (Ministry of Education), Shandong University, Jinan 250012, China


<sup>d</sup> State Key Laboratory of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China

\*To whom correspondence should be addressed: Tel: +86-531-8838-2235; Fax: +86-531-8836-3002; E-mail: hzcaos@sdu.edu.cn; fswang@sdu.edu.cn


### Table of Contents

<sup>1</sup> H NMR spectrum for compound <b>3</b> .....	S2
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>4</b> .....	S3–S4
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>5</b> .....	S5–S6
<sup>1</sup> H NMR spectrum for compound <b>6</b> .....	S7
<sup>1</sup> H NMR spectrum for compound <b>7</b> .....	S8
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>8</b> .....	S9–S10
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>9</b> .....	S11–S12
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>10</b> .....	S13–S14
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>11</b> .....	S15–S16
<sup>1</sup> H NMR spectrum for compound <b>12</b> .....	S17
<sup>1</sup> H NMR spectrum for compound <b>13</b> .....	S18
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>14</b> .....	S19–S20
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>15</b> .....	S21–S22
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>16</b> .....	S23–S24
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>17</b> .....	S25–S26
<sup>1</sup> H NMR spectrum for compound <b>18</b> .....	S27–S28
<sup>1</sup> H and <sup>13</sup> C NMR spectra for compound <b>19</b> .....	S29–S30
HPLC conditions and chromatograms of ST-antigens ( <b>12–17</b> ).....	S31–S32


# $^1\text{H}$ NMR spectrum for GalNAc $\alpha$ ProN<sub>3</sub>, 3




<sup>1</sup>H NMR spectrum for GalNAc6FαProN<sub>3</sub>, 4




<sup>13</sup>C NMR spectrum for GalNAc6FαProN<sub>3</sub>, 4




# <sup>1</sup>H NMR spectrum for Gal6F, 5




<sup>13</sup>C NMR spectrum for Gal6F, 5



<sup>1</sup>H NMR spectrum for Galβ1-3GalNAc, **6**




# $^1\text{H}$ NMR spectrum for Gal $\beta$ 1-3GalNAc $\alpha$ ProN $_3$ , 7







$^1\text{H}$  NMR spectra for Gal $\beta$ 1-3GalNAc6F $\alpha$ ProN $_3$ , 8




$^{13}\text{C}$  NMR spectra for Gal $\beta$ 1-3GalNAc6F $\alpha$ ProN $_3$ , 8




<sup>1</sup>H NMR spectrum for Gal6Fβ1-3GalNAc, 9




<sup>13</sup>C NMR spectrum for Gal6Fβ1-3GalNAc, 9




**<sup>1</sup>H NMR spectrum for Gal6Fβ1–3GalNAcαProN<sub>3</sub>, 10**




<sup>13</sup>C NMR spectrum for Gal6Fβ1-3GalNAcαProN<sub>3</sub>, 10



**<sup>1</sup>H NMR spectrum for Gal6Fβ1-3GalNAc6FαProN<sub>3</sub>, 11**




<sup>13</sup>C NMR spectrum for Gal6Fβ1-3GalNAc6FαProN<sub>3</sub>, 11







<sup>1</sup>H NMR spectrum for Neu5Acα2-3Galβ1-3GalNAc, 12




**<sup>1</sup>H NMR spectrum for Neu5Ac $\alpha$ 2-3Gal $\beta$ 1-3GalNAc $\alpha$ ProN<sub>3</sub>, 13**




<sup>1</sup>H NMR spectrum for Neu5Acα2-3Galβ1-3GalNAc6FαProN<sub>3</sub>, 14




<sup>13</sup>C NMR spectrum for Neu5Acα2-3Galβ1-3GalNAc6FαProN<sub>3</sub>, 14




<sup>1</sup>H NMR spectrum for Neu5Acα2-3Gal6Fβ1-3GalNAc, 15




<sup>13</sup>C NMR spectrum for Neu5Acα2-3Gal6Fβ1-3GalNAc, 15



<sup>1</sup>H NMR spectrum for Neu5Ac $\alpha$ 2-3Gal $\beta$ 1-3GalNAc6F $\alpha$ ProN<sub>3</sub>, 16




<sup>13</sup>C NMR spectrum for Neu5Acα2-3Galβ1-3GalNAc6FαProN<sub>3</sub>, 16







<sup>1</sup>H NMR spectrum for Neu5Acα2-3Gal6Fβ1-3GalNAc6FαProN<sub>3</sub>, 17




<sup>13</sup>C NMR spectrum for Neu5Acα2-3Gal6Fβ1-3GalNAc6FαProN<sub>3</sub>, 17




**<sup>1</sup>H NMR spectrum for Gal2F, 18**



<sup>1</sup>H NMR spectrum for Gal2F-1-P, 19



<sup>13</sup>C NMR spectrum for Gal2F-1-P, 19



## HPLC conditions and chromatograms of ST-antigens (12–17)

### HPLC Conditions:

HPLC instrument: Waters 2695 Separation Module

Column: GE Healthcare Superdex™ Peptide 10/300 GL

Eluent: 0.1 M NH<sub>4</sub>HCO<sub>3</sub>

Flow rate: 0.5 mL/min

Injection volume: 10 μL

Run time: 50 min

### HPLC chromatograms:

